RefDoc
Haut

Faire une nouvelle recherche
Make a new search
Lancer la recherche


Titre du document / Document title

Maintenance Immunotherapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Auteur(s) / Author(s)

RECCHIA Francesco (1 2) ; CANDELORO Giampiero (1) ; DI STASO Mario (3) ; NECOZIONE Stefano (4) ; BISEGNA Roberta (1) ; BRATTA Massimo (2) ; TOMBOLINI Vincenzo (3) ; REA Silvio (2 5) ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

(1) Divisione di Oncologia, ALS-1 Ospedale Civile di Avezzano, ITALIE
(2) Fondazione "Carlo Ferri", Monterotondo, Roma, ITALIE
(3) Radioterapia, Università degli Studi di L'Aquila, ITALIE
(4) Epidemiologia Clinica, Università degli Studi di L'Aquila, ITALIE
(5) Oncologia Chirurgica, Università degli Studi di L'Aquila, ITALIE

Résumé / Abstract

The purpose of this study was to determine the efficacy and safety of a maintenance immunotherapy regimen administered to patients with recurrent/metastatic squamous cell carcinoma of the head and neck (RMHN) who showed clinical benefit from docetaxel, ifosfamide, and cisplatin chemotherapy (DIP). Every 4 weeks, patients with RMHN received 60 mg/m2 docetaxel on day 1, and 1200 mg/m2 ifosfamide and 20 mg/m2 cisplatin on days 1 to 4. Low-dose subcutaneous interleukin-2 and oral 13-cis-retinoic acid were administered as maintenance immunotherapy to patients who showed a clinical benefit (complete or partial response, disease stability). The primary end point was response; secondary end points were progression-free survival, overall survival, toxicity, and evaluations of lymphocytes, natural killer cells, and serum vascular endothelial growth factor (VEGF). After a median follow-up of 22 months, 263 courses of chemotherapy were administered to the 54 patients. The overall response rate was 59%. Forty-two patients (78%) had a clinical benefit and received 185 courses of maintenance immunotherapy. Median progression-free survival and overall survival were 11.1 and 21.8 months, respectively. Statistically significant, progressive increases in lymphocytes and natural killer cells and a decrease in VEGF were observed in patients treated with maintenance immunotherapy. The toxicity was relatively well tolerated and caused no death. Outpatient administration of DIP, followed by low-dose interleukin-2 and 13-cis-retinoic acid, was generally well tolerated and showed promising activity against RMHN. Longitudinal changes in lymphocytes, natural killer cells, and VEGF might be useful biomarkers for response and survival.

Revue / Journal Title

Journal of immunotherapy    ISSN  1524-9557   CODEN JOIMF8 

Source / Source

2008, vol. 31, no4, pp. 413-419 [7 page(s) (article)] (36 ref.)

Langue / Language

Anglais

Editeur / Publisher

Lippincott Williams & Wilkins, Hagerstown, MD, ETATS-UNIS  (1997) (Revue)

Mots-clés anglais / English Keywords

Retinoid

;

Cytokine

;

Platinum II Complexes

;

Oxazaphosphinane derivatives

;

Nitrogen mustard

;

Alkylating agent

;

Taxane derivatives

;

Antimitotic

;

ENT disease

;

Cancer

;

Malignant tumor

;

Antineoplastic agent

;

Isotretinoin

;

Interleukin 2

;

Cisplatin

;

Ifosfamide

;

Docetaxel

;

Head and neck cancer

;

Head and neck squamous cell carcinoma

;

Metastasis

;

Advanced stage

;

Relapse

;

Treatment

;

Immunotherapy

;

Mots-clés français / French Keywords

Rétinoïde

;

Cytokine

;

Platine II Complexe

;

Dérivé de l'oxazaphosphinane

;

Moutarde à l'azote

;

Agent alkylant

;

Dérivé du taxane

;

Antimitotique

;

Pathologie ORL

;

Cancer

;

Tumeur maligne

;

Anticancéreux

;

Isotrétinoïne

;

Interleukine 2

;

Cisplatine

;

Ifosfamide

;

Docétaxel

;

Cancer de la tête et du cou

;

Carcinome épidermoïde de la tête et du cou

;

Métastase

;

Stade avancé

;

Récidive

;

Traitement

;

Immunothérapie

;

Mots-clés espagnols / Spanish Keywords

Retinoide

;

Citoquina

;

Platino II Complejo

;

Oxazafosfinano derivado

;

Mostaza al nitrógeno

;

Agente alquilante

;

Taxane derivado

;

Antimitótico

;

ORL patología

;

Cáncer

;

Tumor maligno

;

Anticanceroso

;

Isotretinoína

;

Interleuquina 2

;

Cisplatino

;

Ifosfamida

;

Docetaxel

;

Cáncer de cabeza y cuello

;

Carcinoma epidermoideo cabeza cuello

;

Metástasis

;

Estadio avanzado

;

Recaida

;

Tratamiento

;

Inmunoterapia

;

Mots-clés d'auteur / Author Keywords

advanced head and neck cancer

;

docetaxel

;

ifosfamide

;

cisplatin

;

interleukin-2

;

13-cis-retinoic acid

;

Localisation / Location

INIST-CNRS, Cote INIST : 19700, 35400017277790.0100

Nº notice refdoc (ud4) : 20280847



Faire une nouvelle recherche
Make a new search
Lancer la recherche
Bas